Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects-Reference-Cited by-同舟云学术

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Published:2007-02 Issue:2 Volume:47 Page:218-226
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Kubitza Dagmar,Becka Michael,Zuehlsdorf Michael,Mueck Wolfgang

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference22 articles.

1. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial;Buller;Ann Intern Med.,2004

2. Patient-specific factors predictive of warfarin dosage requirements;Absher;Ann Pharmacother,2002

3. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population;Garcia;Chest,2005

4. Obesity;Haslam;Lancet,2005

5. National Institute of Diabetes & Digestive & Kidney Disease Weight-control information network. Statistics related to overweight and obesity 2005 http://win.niddk.nih.gov/statistics/index.htm

Cited by 299 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Anticoagulants Beyond Warfarin;Annual Review of Pharmacology and Toxicology;2024-01-23

2. Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism;Thrombosis Research;2024-01

3. Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications;TH Open;2024-01

4. Direct Oral Anticoagulants in Special Patient Populations;Journal of Clinical Medicine;2023-12-29

5. Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-12-19